Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers
Celonic AG and APIT Laboratories GmbH have announced a commercial license agreement for of a new biopharmaceutical compound for the treatment of cancer. The anti-tumor protein, originally isolated from the defensive ink of a sea slug, attacks tumor cells in a threefold mechanism of action through the enzymatic production of reactive oxygen species and the deprivation of amino acids specifically required by tumor cells.
In vitro and in vivo experiments show that APIT efficiently destroys various kinds of cancers and could potentially also be used for the treatment of cancer becoming resistant to chemotherapy. This agreement grants Celonic the exclusive and worldwide rights for the development and marketing of the new pharmaceutical drug.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.